🇮🇳September 25, 2026·17h agoIndustry

natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26

Publisher

Natco Pharma

India

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Natco Pharma
Region: India
Scope: Industry
Published: September 25, 2026

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on natcopharma.co.in

Leave the platform to read the original full article on the publisher site.

Source: Natco Pharma

Scope: Industry

Open original article

Related coverage

More related coverage

Techcyte/1h ago

Techcyte Launches Microsoft Teams Meetings from Fusion AP

Bristol-Myers Squibb News/3h ago

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Certara/4h ago

Marvin is now fully integrated as the unified drawing experience across Certara’s Discovery portfolio

Merck & Co. (MSD) News/6h ago

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)